Beta Drugs Limited — Others, 15-05-2025: Statement of deviation(s) or variation(s) under Reg. 32

Beta Drugs Limited has announced a board meeting to review the financial results for the quarter and half-year. The company reports no deviation in the utilization of ₹11 crore raised through its recent preferential issue, with funds deployed as planned for facility upgrades in subsidiaries, new R&D setup, geographical expansion, manufacturing capex, and general corporate purposes. The Audit Committee and Board have confirmed compliance, reflecting disciplined capital management that supports its growth and expansion strategy, providing confidence to shareholders on prudent fund usage.